By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Convergence Pharmaceuticals 

Babraham Research Campus

Cambridge    CB22 3AT  United Kingdom
Phone: +44-(0)1223-755-501 Fax: +44-(0)1223-497-114


SEARCH JOBS


Industry
Pharmaceutical

Segment
Pharmaceuticals





Company News
Convergence Pharmaceuticals' Novel Sodium Channel Blocker CNV1014802 Shows Excellent Efficacy And Safety In Ground-Breaking Phase II Trigeminal Neuralgia Study 6/16/2014 7:43:14 AM
GlaxoSmithKline (GSK) Spin-Off Convergence Pharmaceuticals Gears Up For Possible Listing 6/16/2014 6:30:13 AM
Evotec AG (EVTG.F) And Convergence Pharmaceuticals Form Integrated Pain Alliance 3/31/2014 10:10:41 AM
Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802 7/30/2013 8:14:54 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia 7/8/2013 9:54:48 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated With Post-Herpetic Neuralgia 4/23/2013 9:48:49 AM
Convergence Pharmaceuticals Announces Successful Interim Data From Ground-Breaking Phase II Trigeminal Neuralgia Study 3/27/2013 9:26:32 AM
Convergence Pharmaceuticals Announces Successful Completion of Phase I for CNV2197944 and Plans Phase II Studies in Neuropathic Pain 7/18/2012 10:08:05 AM
Convergence Pharmaceuticals Announces Start of Phase II Study for CNV1014802 for Trigeminal Neuralgia 3/19/2012 9:06:50 AM
Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944 11/21/2011 7:17:17 AM
12
//-->